Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Partial Adenosine A1 Agonist in Heart Failure.
Dinh W, Albrecht-Küpper B, Gheorghiade M, Voors AA, van der Laan M, Sabbah HN. Dinh W, et al. Among authors: gheorghiade m. Handb Exp Pharmacol. 2017;243:177-203. doi: 10.1007/164_2016_83. Handb Exp Pharmacol. 2017. PMID: 27770217 Review.
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
Voors AA, Shah SJ, Bax JJ, Butler J, Gheorghiade M, Hernandez AF, Kitzman DW, McMurray JJV, Wirtz AB, Lanius V, van der Laan M, Solomon SD. Voors AA, et al. Among authors: gheorghiade m. Eur J Heart Fail. 2018 Nov;20(11):1601-1610. doi: 10.1002/ejhf.1295. Epub 2018 Sep 17. Eur J Heart Fail. 2018. PMID: 30225882 Free article. Clinical Trial.
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE, Macarie C, Ruzyllo W, Bacchieri A, Valentini G, Bianchetti M, Pang PS, Harinstein ME, Sabbah HN, Filippatos GS, Gheorghiade M; HORIZON-HF investigators. Blair JE, et al. Among authors: gheorghiade m. Am J Ther. 2008 May-Jun;15(3):231-40. doi: 10.1097/MJT.0b013e31816d9186. Am J Ther. 2008. PMID: 18496261 Clinical Trial.
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Khan H, et al. Among authors: gheorghiade m. Heart Fail Rev. 2009 Dec;14(4):277-87. doi: 10.1007/s10741-009-9136-z. Epub 2009 Feb 24. Heart Fail Rev. 2009. PMID: 19238540 Review.
Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.
Gheorghiade M, Vaduganathan M, Ambrosy A, Böhm M, Campia U, Cleland JG, Fedele F, Fonarow GC, Maggioni AP, Mebazaa A, Mehra M, Metra M, Nodari S, Pang PS, Ponikowski P, Sabbah HN, Komajda M, Butler J. Gheorghiade M, et al. Heart Fail Rev. 2013 Mar;18(2):107-22. doi: 10.1007/s10741-012-9315-1. Heart Fail Rev. 2013. PMID: 22581217 Review.
719 results